IHII_banner art

Institute for Human Infections & Immunity (IHII)

UTMB Research on COVID-19

Thanks to our unusually strong expertise in coronaviruses (three of our faculty scientists focus on these viruses and many others have extensive coronavirus experience) and our unique high containment facilities, UTMB is at the forefront of the emergency response to the COVID-19 outbreak and is already conducting research to understand the disease as well as to develop vaccines and therapeutics. Click here to view a list of the major research projects underway to study the new coronavirus (SARS-CoV-2, the cause of the disease called COVID-19) »

IHII Mission Statement

Scott_Weaver_3x4The world-class infectious disease research programs of the University of Texas Medical Branch are breaking new ground in understanding the nature of infectious diseases, and are working to translate new research concepts into products aimed at controlling emerging infectious diseases and mitigating their effects on society. The programs of the Institute for Human Infections and Immunity (IHII) are the hub of infectious disease research at UTMB. The IHII’s mission is to coordinate, facilitate and enhance the activities of UTMB’s research centers and programs that focus on advancing the fields of infection and immunity.

IHII programs and centers include the Galveston National Laboratory (GNL), the Center for Biodefense & Emerging Infectious Diseases (CBEID), the Center for Tropical Diseases (CTD), the Sealy Institute for Vaccine Sciences (SIVS), the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA), the McLaughlin Endowment for Infection and Immunity, the Western Gulf Center of Excellence for Vector-Borne Diseases (WGCVBD), West African Center of Emerging Infectious Diseases, Sealy Center for Microbiome Research, and the W.M. Keck Center for Virus Imaging in BSL-3.

Scott C. Weaver, MS, PhD

Scott C. Weaver, MS, PhD

Follow @ihii_utmb on Twitter

  Data Acquisition Grant Instructions and Application Packet (FY2022)
Application due date: February 14, 2022
Anticipated review date: March 1, 2022
Anticipated Funding Period: March 15, 2022 to August 31, 2022

  UTMB Health Technology Commercialization Program
Pre-application workshops: Virtually - Nov. 18 & Dec. 16 from Noon -1 pm. To register, please contact Lanette Harris: ldharris@utmb.edu.
Pre-proposal submission: Please submit electronically to Dr. Sundeep Mattamana, Email: sumattam@utmb.edu no later than 5 pm on January 18, 2022.

  T32 Training Program Opportunity

  IHII Phase II Research Grant Program

The Phase II program is replacing the COVID grant program. The Phase II applications will be accepted on a rolling basis through February 1st at 5pm. Phase II: IHII FY2022 Research Grants Program